Brain metastases in adult patients with melanoma of unknown primary in the Netherlands (2011–2020)
暂无分享,去创建一个
M. Bekkenk | M. Louwman | V. Ho | S. V. van Zanten | F. D. De Vos | C. Loef | C. S. Padilla | T. W. A. N. Mooijenkind | W. A. Minnaard | S. E. M. V. van Zanten | Veldhuijzen van Zanten | Padilla | Ho | Mooijenkind | Louwman | Vos | Bekkenk | Minnaard | Loef
[1] J. Grob,et al. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort. , 2022, Journal of the American Academy of Dermatology.
[2] V. Ho,et al. Prognostic factors among patients with brain metastases from cancer of unknown primary site , 2022, Journal of Neuro-Oncology.
[3] H. Tawbi,et al. Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real‐world study , 2021, Cancer medicine.
[4] R. Dummer,et al. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. , 2021, European journal of cancer.
[5] M. Aboian,et al. Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis , 2021, Journal of Neuro-Oncology.
[6] G. Hospers,et al. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy , 2021, Cancer Immunology, Immunotherapy.
[7] J. Greenlee,et al. Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy , 2021, Cancers.
[8] A. Amini,et al. Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling , 2020, Annals of Surgical Oncology.
[9] D. Schadendorf,et al. Melanoma brain metastases - Interdisciplinary management recommendations 2020. , 2020, Cancer treatment reviews.
[10] M. Donia,et al. The real‐world outcome of metastatic melanoma: Unknown primary vs. known cutaneous , 2019, International journal of cancer.
[11] T. Gambichler,et al. Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results , 2019, Oncoimmunology.
[12] C. Verhoef,et al. Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population‐based study , 2019, International journal of cancer.
[13] M. Atkins,et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.
[14] J. Wilmott,et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. , 2018, The Lancet. Oncology.
[15] V. Sondak,et al. High frequency of brain metastases after adjuvant therapy for high‐risk melanoma , 2017, Cancer medicine.
[16] Ying Zhang,et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. , 2017, The Lancet. Oncology.
[17] R. Braun,et al. Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching? , 2017, Melanoma research.
[18] M. Gore,et al. Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases , 2015, Pigment cell & melanoma research.
[19] R. Dummer,et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. , 2014, European journal of cancer.
[20] L. Kiemeney,et al. Melanoma of unknown primary origin: a population-based study in the Netherlands. , 2013, European journal of cancer.
[21] J. Wolchok,et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[22] P. Hwu,et al. Prognostic factors for survival in melanoma patients with brain metastases , 2011, Cancer.
[23] D. Morton,et al. Improved survival for stage IV melanoma from an unknown primary site. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Berg,et al. MALIGNANT MELANOMA OF UNKNOWN PRIMARY ORIGIN. , 1963, Surgery, gynecology & obstetrics.
[25] Yoon Young Choi,et al. Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. , 2015, Journal of the American Academy of Dermatology.
[26] P. Allen. ICDO — International Classification of Diseases for Oncology , 1991 .